{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dutt M"],"funding":["Cancer Research UK","Medical Research and Materiel Command","UCLH Biomedical Research Centre","Medical Research Council","QIMR Berghofer Medical Research Institute","National Institute for Health Research (NIHR)","National Health and Medical Research Council","Ovarian Cancer Australia"],"pagination":["e2200114"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7615076"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(4)"],"pubmed_abstract":["<h4>Purpose</h4>This study aimed to identify serum glycoprotein biomarkers for early detection of high-grade serous ovarian cancer (HGSOC), the most common and aggressive histotype of ovarian cancer.<h4>Experimental design</h4>The glycoproteomics pipeline lectin magnetic bead array (LeMBA)-mass spectrometry (MS) was used in age-matched case-control serum samples. Clinical samples collected at diagnosis were divided into discovery (n = 30) and validation (n = 98) sets. We also analysed a set of preclinical sera (n = 30) collected prior to HGSOC diagnosis in the UK Collaborative Trial of Ovarian Cancer Screening.<h4>Results</h4>A 7-lectin LeMBA-MS/MS discovery screen shortlisted 59 candidate proteins and three lectins. Validation analysis using 3-lectin LeMBA-multiple reaction monitoring (MRM) confirmed elevated A1AT, AACT, CO9, HPT and ITIH3 and reduced A2MG, ALS, IBP3 and PON1 glycoforms in HGSOC. The best performing multimarker signature had 87.7% area under the receiver operating curve, 90.7% specificity and 70.4% sensitivity for distinguishing HGSOC from benign and healthy groups. In the preclinical set, CO9, ITIH3 and A2MG glycoforms were altered in samples collected 11.1 ± 5.1 months prior to HGSOC diagnosis, suggesting potential for early detection.<h4>Conclusions and clinical relevance</h4>Our findings provide evidence of candidate early HGSOC serum glycoprotein biomarkers, laying the foundation for further study in larger cohorts."],"journal":["Proteomics. Clinical applications"],"pubmed_title":["Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer."],"pmcid":["PMC7615076"],"funding_grant_id":["DAMD17‐01‐1‐0729","G0801228","N/A","ID400281","ID199600","ID400413","MC_UU_00004/01","C1479/A2884","G9901012"],"pubmed_authors":["Menon U","Hartel G","Hooper JD","Australian Ovarian Cancer Study Group","Mohamed A","Richards RS","Gentry-Maharaj A","Shah AK","Dutt M","Apostolidou S","Hill MM","Perrin LC"],"additional_accession":[]},"is_claimable":false,"name":"Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer.","description":"<h4>Purpose</h4>This study aimed to identify serum glycoprotein biomarkers for early detection of high-grade serous ovarian cancer (HGSOC), the most common and aggressive histotype of ovarian cancer.<h4>Experimental design</h4>The glycoproteomics pipeline lectin magnetic bead array (LeMBA)-mass spectrometry (MS) was used in age-matched case-control serum samples. Clinical samples collected at diagnosis were divided into discovery (n = 30) and validation (n = 98) sets. We also analysed a set of preclinical sera (n = 30) collected prior to HGSOC diagnosis in the UK Collaborative Trial of Ovarian Cancer Screening.<h4>Results</h4>A 7-lectin LeMBA-MS/MS discovery screen shortlisted 59 candidate proteins and three lectins. Validation analysis using 3-lectin LeMBA-multiple reaction monitoring (MRM) confirmed elevated A1AT, AACT, CO9, HPT and ITIH3 and reduced A2MG, ALS, IBP3 and PON1 glycoforms in HGSOC. The best performing multimarker signature had 87.7% area under the receiver operating curve, 90.7% specificity and 70.4% sensitivity for distinguishing HGSOC from benign and healthy groups. In the preclinical set, CO9, ITIH3 and A2MG glycoforms were altered in samples collected 11.1 ± 5.1 months prior to HGSOC diagnosis, suggesting potential for early detection.<h4>Conclusions and clinical relevance</h4>Our findings provide evidence of candidate early HGSOC serum glycoprotein biomarkers, laying the foundation for further study in larger cohorts.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2026-06-08T06:38:49.058Z","creation":"2026-06-08T03:14:35.125Z"},"accession":"S-EPMC7615076","cross_references":{"pubmed":["37147936"],"doi":["10.1002/prca.202200114"]}}